Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · medullo-epn-umap@date-based

BS_2SFTWNVE

Med · Medulloblastoma

44b8cca1-96d3-5191-a2c8-b7b537d697eb

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
Med
cancer_type_detailed
—
subtype
Medulloblastoma
cancer_type
Med
subtype
Medulloblastoma
os_event
false
age_years
9.274
sex
M
umap1_2d
5.940932702
umap2_2d
5.953151896
umap1_3d
3.206587008
umap2_3d
-0.185537809
umap3_3d
-2.580011337
dataset
Med-CBTN

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • COMPLEMENT+0.240
  • HEDGEHOG_SIGNALING+0.240
  • PROTEIN_SECRETION+0.200
  • HEME_METABOLISM+0.190
  • COAGULATION+0.180
  • ESTROGEN_RESPONSE_EARLY+0.160
  • XENOBIOTIC_METABOLISM+0.150
  • INTERFERON_ALPHA_RESPONSE+0.140
  • KRAS_SIGNALING_UP+0.140
  • INFLAMMATORY_RESPONSE+0.120

Top 10 suppressed

  • MYC_TARGETS_V2-0.730
  • E2F_TARGETS-0.690
  • G2M_CHECKPOINT-0.630
  • MYC_TARGETS_V1-0.620
  • UNFOLDED_PROTEIN_RESPONSE-0.420
  • DNA_REPAIR-0.410
  • MTORC1_SIGNALING-0.330
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.310
  • MITOTIC_SPINDLE-0.280
  • OXIDATIVE_PHOSPHORYLATION-0.260

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MDT-AP-3030
medullo-epn-umap@date-based
MedMedulloblastoma0.882
2MDT-AP-3098
medullo-epn-umap@date-based
MedMedulloblastoma0.871
3TCGA-86-7714-01A-12R-2170-07
lung-landscapes@6
—cohortA10.853
4TCGA-NJ-A55O-01A-11R-A262-07
lung-landscapes@6
—cohortA20.845
5TCGA-55-8513-01A-11R-2403-07
lung-landscapes@6
—cohortA10.840
6TCGA-O1-A52J-01A-11R-A262-07
lung-landscapes@6
—cohortA10.840
7C3N-03038
lung-landscapes@6
—cohortA10.839
8MDT-AP-0810
medullo-epn-umap@date-based
MedMedulloblastoma0.837
9BS_KN92S7YQ
medullo-epn-umap@date-based
MedMedulloblastoma0.837
10TCGA-50-5935-01A-11R-1755-07
lung-landscapes@6
—cohortA10.837

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 22 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
COMPLEMENT0.240Inavolisib— uncovered
HEDGEHOG_SIGNALING0.240Inavolisib— uncovered
PROTEIN_SECRETION0.200Remibrutinib— uncovered
HEME_METABOLISM0.190Temsirolimus— uncovered
COAGULATION0.180Binimetinib— uncovered
ESTROGEN_RESPONSE_EARLY0.160Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.150Inavolisib— uncovered
INTERFERON_ALPHA_RESPONSE0.140Inavolisib— uncovered
KRAS_SIGNALING_UP0.140Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.120Idelalisib— uncovered
INTERFERON_GAMMA_RESPONSE0.120Idelalisib— uncovered
UV_RESPONSE_DN0.110Inavolisib— uncovered
NOTCH_SIGNALING0.100Inavolisib— uncovered
KRAS_SIGNALING_DN0.090Remibrutinib— uncovered
ANDROGEN_RESPONSE0.070Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.070Inavolisib— uncovered
MYOGENESIS0.070Inavolisib— uncovered
BILE_ACID_METABOLISM0.050Inavolisib— uncovered
PANCREAS_BETA_CELLS0.050Cobimetinib— uncovered
ESTROGEN_RESPONSE_LATE0.040Idelalisib— uncovered